{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:34:08Z","timestamp":1788618848409,"version":"build-2803163510"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T00:00:00Z","timestamp":1598745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium\u2013glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and without type 2 diabetes (T2D). This analysis reports the baseline characteristics of those recruited, comparing them with those enrolled in other trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In DAPA-CKD, 4304 participants with a urinary albumin:creatinine ratio (UACR) \u2265200\u2009mg\/g and estimated glomerular filtration rate (eGFR) between 25 and 75\u2009mL\/min\/1.73\u2009m2 were randomized to dapagliflozin 10\u2009mg once daily or placebo. Mean eGFR was 43.1\u2009mL\/min\/1.73\u2009m2 and median UACR was 949\u2009mg\/g (108\u2009mg\/mmol).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 2906 participants (68%) had a diagnosis of T2D and of these, 396 had CKD ascribed to a cause other than diabetes. The most common causes of CKD after diabetes (n\u2009=\u20092510) were ischaemic\/hypertensive nephropathy (n\u2009=\u2009687) and chronic glomerulonephritis (n\u2009=\u2009695), of which immunoglobulin A nephropathy (n\u2009=\u2009270) was the most common. A total of 4174 participants (97%) were receiving an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, 1882 (43.7%) diuretics, 229 (5.3%) mineralocorticoid receptor antagonists and 122 (2.8%) glucagon-like peptide 1 receptor agonists. In contrast to the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), the DAPA-CKD trial enrolled participants with CKD due to diabetes and to causes other than diabetes. The mean eGFR of participants in the DAPA-CKD trial was 13.1\u2009mL\/min\/1.73\u2009m2 lower than in CREDENCE, similar to that in the Finerenone in Reducing Kidney Failure and Disease Progression in DKD (FIDELIO-DKD) trial and the Study Of diabetic Nephropathy with AtRasentan (SONAR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Participants with a wide range of underlying kidney diseases receiving renin\u2013angiotensin system blocking therapy have been enrolled in the DAPA-CKD trial. The trial will examine the efficacy and safety of dapagliflozin in participants with CKD Stages 2\u20134 and increased albuminuria, with and without T2D.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfaa234","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T07:09:35Z","timestamp":1597043375000},"page":"1700-1711","source":"Crossref","is-referenced-by-count":171,"title":["The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics"],"prefix":"10.1093","volume":"35","author":[{"given":"David C","family":"Wheeler","sequence":"first","affiliation":[{"name":"Department of Renal Medicine, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bergur V","family":"Stefansson","sequence":"additional","affiliation":[{"name":"Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Batiushin","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Rostov State Medical University, Rostov, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleksandr","family":"Bilchenko","sequence":"additional","affiliation":[{"name":"Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z I","family":"Cherney","sequence":"additional","affiliation":[{"name":"Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada"},{"name":"Department of Medicine, Division of Nephrology, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn M","family":"Chertow","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA"},{"name":"Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Douthat","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Privado Universitario de Cordoba, Cordoba, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie P","family":"Dwyer","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Escudero","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Hospital Arzobispo Loayza, Cayetano Heredia University, Lima, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0255-6710","authenticated-orcid":false,"given":"Roberto","family":"Pecoits-Filho","sequence":"additional","affiliation":[{"name":"School of Medicine, Pontificia Universidade Catolica do Parana, Curitiba, Brazil"},{"name":"Arbor Research Collaborative for Health, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Furuland","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences Renal Unit, Uppsala University Hospital, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"G\u00f3rriz","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Clinic Hospital, INCLIVA, University of Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Greene","sequence":"additional","affiliation":[{"name":"Study Design and Biostatistics Center, University of Utah Health Sciences, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Haller","sequence":"additional","affiliation":[{"name":"Hannover Medical School, Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan Fan","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Southern Medical University, National Clinical Research Center for Kidney Disease, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Wook","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology, Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rey","family":"Isidto","sequence":"additional","affiliation":[{"name":"Healthlink Medical, Dental, Surgical Clinics and Diagnostics Center, Iloilo City, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khullar","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Renal Transplant Medicine, Max Super Speciality Hospital, Saket, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3387-2123","authenticated-orcid":false,"given":"Patrick B","family":"Mark","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J V","family":"McMurray","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kashihara","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Kawasaki Medical School, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Nowicki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hypertension and Kidney Transplantation, Medical University of \u0141\u00f3d\u017a, \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Persson","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center Copenhagen, Gentofte, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Correa-Rotter","sequence":"additional","affiliation":[{"name":"National Medical Science and Nutrition Institute Salvador Zubir\u00e1n, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center Copenhagen, Gentofte, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D","family":"Toto","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik","family":"Umanath","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI, USA"},{"name":"Division of Nephrology and Hypertension, Wayne State University, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pham","family":"Van Bui","sequence":"additional","affiliation":[{"name":"Pham Ngoc Thach Medicine University, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Wittmann","sequence":"additional","affiliation":[{"name":"Second Department of Medicine and Nephrology-Diabetes Center, University of P\u00e9cs Medical School, P\u00e9cs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Lindberg","sequence":"additional","affiliation":[{"name":"Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C David","family":"Sj\u00f6str\u00f6m","sequence":"additional","affiliation":[{"name":"Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Langkilde","sequence":"additional","affiliation":[{"name":"Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J L","family":"Heerspink","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,30]]},"reference":[{"key":"2020100618543996500_gfaa234-B1","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2020100618543996500_gfaa234-B2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2020100618543996500_gfaa234-B3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2020100618543996500_gfaa234-B4","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2020100618543996500_gfaa234-B5","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"2020100618543996500_gfaa234-B6","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1152\/ajpregu.00357.2011","article-title":"Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat","volume":"302","author":"Thomson","year":"2012","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2020100618543996500_gfaa234-B7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"2020100618543996500_gfaa234-B8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"key":"2020100618543996500_gfaa234-B9","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial","volume":"8","author":"Cherney","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2020100618543996500_gfaa234-B10","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"2020100618543996500_gfaa234-B11","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med"},{"key":"2020100618543996500_gfaa234-B12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N Engl J Med"},{"key":"2020100618543996500_gfaa234-B13","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/ndt\/gfz290","article-title":"Rationale and protocol of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial","volume":"35","author":"Heerspink","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2020100618543996500_gfaa234-B14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000503713","article-title":"Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial","volume":"50","author":"Bakris","year":"2019","journal-title":"Am J Nephrol"},{"key":"2020100618543996500_gfaa234-B15","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/dom.13245","article-title":"Rationale and protocol of the study of diabetic nephropathy with AtRasentan (SONAR) trial: a clinical trial design novel to diabetic nephropathy","volume":"20","author":"Heerspink","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2020100618543996500_gfaa234-B16","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/ckj\/sfy090","article-title":"The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study","volume":"11","author":"Herrington","year":"2018","journal-title":"Clin Kidney J"},{"key":"2020100618543996500_gfaa234-B17"},{"key":"2020100618543996500_gfaa234-B18","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"2020100618543996500_gfaa234-B19","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"2020100618543996500_gfaa234-B20","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.ekir.2019.08.007","article-title":"Implementing the kidney health initiative surrogate efficacy endpoint in patients with IgA nephropathy (the PROTECT trial)","volume":"4","author":"Barratt","year":"2019","journal-title":"Kidney Int Rep"},{"key":"2020100618543996500_gfaa234-B21"},{"key":"2020100618543996500_gfaa234-B22","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"2020100618543996500_gfaa234-B23"},{"key":"2020100618543996500_gfaa234-B24","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1053\/j.ajkd.2013.09.016","article-title":"Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes with the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT","volume":"63","author":"Lambers Heerspink","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2020100618543996500_gfaa234-B25","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000484633","article-title":"The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics","volume":"46","author":"Jardine","year":"2017","journal-title":"Am J Nephrol"},{"key":"2020100618543996500_gfaa234-B26","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2215\/CJN.02510213","article-title":"The modern spectrum of renal biopsy findings in patients with diabetes","volume":"8","author":"Sharma","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020100618543996500_gfaa234-B27"},{"key":"2020100618543996500_gfaa234-B28","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1681\/ASN.2018010091","article-title":"DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS","volume":"29","author":"Trachtman","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2020100618543996500_gfaa234-B29"},{"key":"2020100618543996500_gfaa234-B30","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamainternmed.2018.0292","article-title":"Association of metformin use with risk of lactic acidosis across the range of kidney function: a community-based cohort study","volume":"178","author":"Lazarus","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2020100618543996500_gfaa234-B31","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1111\/dom.13315","article-title":"Baseline characteristics and enrichment results from the SONAR trial","volume":"20","author":"Heerspink","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2020100618543996500_gfaa234-B32"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/35\/10\/1700\/33840198\/gfaa234.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/35\/10\/1700\/33840198\/gfaa234.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T18:55:27Z","timestamp":1602010527000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/35\/10\/1700\/5899227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,30]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,8,30]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaa234","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,8,30]]}}}